As of 2025-07-09, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -1.20 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 22.99 USD, the upside of Summit Therapeutics Inc is -105.21%.
Based on its market price of 22.99 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 105.21%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
Range | Selected | Upside | |
a | |||
Fair Value | -1.20 - -1.20 | -1.20 | -105.21% |
P/E | (2.46) - (4.46) | (3.21) | -114.0% |
DDM - Stable | (1.56) - (4.63) | (3.10) | -113.5% |
DDM - Multi | (0.10) - (0.23) | (0.14) | -100.6% |
Market Cap (mil) | 17,073.98 |
Beta | 3.25 |
Outstanding shares (mil) | 742.67 |
Enterprise Value (mil) | 16,862.46 |
Market risk premium | 4.60% |
Cost of Equity | 11.69% |
Cost of Debt | 5.00% |
WACC | 7.68% |